Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Keisei Anan"'
Autor:
Ryota Matsuda, Michiyo Saimura, Keisei Anan, Kento Katsuyama, Yuki Tahara, Kanako Kurata, Kohei Horioka, Mitsuhiro Nakamoto, Kenichiro Koga, Shoshu Mitsuyama, Eiichi Sato, Shinichi Wakamatsu, Sadafumi Tamiya
Publikováno v:
Surgical Case Reports, Vol 9, Iss 1, Pp 1-6 (2023)
Abstract Background Primary angiosarcomas of the breast are rare and highly aggressive. We herein report a rare case of multiple angiosarcomas detected concurrently in both breasts. Case presentation A 49-year-old woman visited a doctor after noticin
Externí odkaz:
https://doaj.org/article/08c592ec76f342af8b31179c20f75139
Autor:
Misato Masuyama, Norikazu Masuda, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17718-17730 (2023)
Abstract Background The role of endocrine therapy in the treatment of patients in a postmenopausal hormonal state and with estrogen receptor (ER)‐positive, human epidermal growth factor receptor 2 (HER2)‐positive advanced or metastatic breast can
Externí odkaz:
https://doaj.org/article/caeec8fc425642ad8dfd47e91b38c921
Autor:
Yasutaka Kawakita, Keisei Anan, Kanako Kurata, Kenichiro Koga, Michiyo Saimura, Sadafumi Tamiya, Kazuyoshi Nishihara, Shoshu Mitsuyama, Toru Nakano
Publikováno v:
Surgical Case Reports, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract Background Few reports of inflammatory myofibroblastic tumor (IMT) of the breast have been published worldwide. Furthermore, primary anaplastic lymphoma kinase (ALK)-positive IMT of the breast is extremely rare. To date, only six patients wi
Externí odkaz:
https://doaj.org/article/8d3b85c9df434b428078b15887e88096
Autor:
Kanako Kurata, Keisei Anan, Nami Ishikawa, Kenichiro Koga, Michiyo Saimura, Kazuyoshi Nishihara, Toshimitsu Iwashita, Shoshu Mitsuyama, Sadafumi Tamiya, Hideyuki Watanabe, Yutaka Koga, Hidetaka Yamamoto, Yoshinao Oda, Toru Nakano
Publikováno v:
Surgical Case Reports, Vol 4, Iss 1, Pp 1-5 (2018)
Abstract Background Primary sarcomas of the breast are rare and account for less than 1% of all primary breast malignancies. We experienced a case of extraskeletal osteosarcoma of the breast that had a unique clinical course and remarkable findings o
Externí odkaz:
https://doaj.org/article/d17f0c96ef80425a9fe1627b9c402c9e
Autor:
Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Publikováno v:
Japanese Journal of Clinical Oncology. 52:545-553
Background The Safari study (UMIN000015168) was a retrospective, multicenter study in which 1072 consecutive cases of estrogen receptor-positive advanced breast cancer treated using 500 mg fulvestrant were registered. We previously reported the relat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af3d12570b626583bda92aa96379fa7a
https://doi.org/10.1093/jjco/hyac022
https://doi.org/10.1093/jjco/hyac022
Autor:
Kaho Utsunomiya, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Publikováno v:
Cancer Research. 83:P2-03
Background: Only old evidence exist to back up the use of medroxyprogesterone acetate (MPA) in endocrine therapy. Therefore, this study aimed to explore the factors that influence the time to treatment failure (TTF) of MPA in real world settings as l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edad0cb166cd7daed7398c5633779ab3
https://doi.org/10.1158/1538-7445.sabcs22-p2-03-15
https://doi.org/10.1158/1538-7445.sabcs22-p2-03-15
Autor:
Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Publikováno v:
Japanese journal of clinical oncology.
BackgroundOnly old evidence exists to back up the use of medroxyprogesterone acetate. Therefore, this study aimed to explore the factors that influence the time to treatment failure of medroxyprogesterone acetate in real-world settings as late-line t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f53de2616003bdaa6da41ca8de25c0e3
https://pubmed.ncbi.nlm.nih.gov/36484305
https://pubmed.ncbi.nlm.nih.gov/36484305
Autor:
Tatsuya Uga, Toshihiro Tanaka, Kyuichirou Miyara, Kazuo Tamura, Maki Tanaka, Shoshu Mitsuyama, Yoshihiko Kamada, Kbc-Sg, Keisei Anan, Hidemi Furusawa, Yoshiaki Sagara, Yuichirou Kai
Publikováno v:
Anticancer Research. 40:4779-4785
Background/aim Irinotecan is rarely used on the metastatic breast cancer (MBC) setting. S-1 is an oral mixture of tegafur, gimeracil and oteracil. We conducted this pilot study to assess efficacy and safty of chemotherapy with combined irinotecan and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a61fd55f99c3843ca47027ec2b72f1bc
https://doi.org/10.21873/anticanres.14480
https://doi.org/10.21873/anticanres.14480
Autor:
Masakazu Toi, Shinji Ohno, Yutaka Yamamoto, Toshimi Takano, Hiroko Yamashita, Eriko Tokunaga, Tomomi Fujisawa, Nobuaki Sato, Yoshinori Ito, Yoshie Hasegawa, Kenjiro Aogi, Norikazu Masuda, Takahiro Nakayama, Hidetoshi Kawaguchi, Daisuke Yotsumoto, Masaya Hattori, Miki Yamaguchi, Shigehira Saji, Seigo Nakamura, Keisei Anan, Toshinari Yamashita, Shoichiro Ohtani, Satoshi Morita
Publikováno v:
Cancer Research. 80:P5-11
Background: There are now many treatment options for estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC). However, there are few reports indicating the optimal treatment sequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f0101cc52cb607790627d8b09dc7907
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-11
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-11
Autor:
Takahiro Nakayama, Daisuke Yotsumoto, Hiroko Yamashita, Yoshinori Ito, Shigehira Saji, Masaya Hattori, Masakazu Toi, Miki Yamaguchi, Nobuaki Sato, Satoshi Morita, Toshimi Takano, Tomomi Fujisawa, Kenjiro Aogi, Shinji Ohno, Yutaka Yamamoto, Keisei Anan, Yoshie Hasegawa, Eriko Tokunaga, Hidetoshi Kawaguchi, Misato Hagi, Shoichiro Ohtani, Norikazu Masuda, Seigo Nakamura, Toshinari Yamashita
Publikováno v:
Cancer Research. 80:P5-11
Background: After the CONFIRM trial, fulvestrant 500 mg (F500) became a standard treatment for patients with estrogen receptor positive (ER+) advanced/metastatic breast cancer (AMBC). The JBCRG-C06 Safari study (UMIN 000015168) showed that earlier F5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbe51dd1e0809bd16a3a0cdda4f3c8df
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-13
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-13